REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy

REDWOOD-HCM Topline Results

Efficacy of Omecamtiv Mecarbil in HFrEF According to NT-proBNP Level: Insights from the GALACTIC-HF Trial

Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from GALACTIC-HF

Influence of Atrial Fibrillation on Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure: The GALACTIC-HF Trial

Impact of Ejection Fraction on the Therapeutic Effect of Omecamtiv Mecarbil in Patients with Reduced Ejection Fraction: A Secondary Analysis from GALACTIC-HF

Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF

GALACTIC-HF: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC‐HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials

CV Outcomes Trial for Omecamtiv Mecarbil Enrolls 8,256 Patients With HFrEF